Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
Mohit Sodhi, Ramin Rezaeianzadeh, Abbas Kezouh, Mahyar Etminan
Abstract
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.
Topics & Concepts
MedicineSemaglutideLiraglutideAdverse effectWeight lossGlucagonGlucagon-like peptide 1 receptorGlucagon-like peptide-1Internal medicineEndocrinologyExenatideAgonistReceptorDiabetes mellitusType 2 diabetesObesityInsulinDiabetes Treatment and ManagementGastric Cancer Management and OutcomesPharmacology and Obesity Treatment